What are the perioperative concerns and management for a patient undergoing mastectomy who has rheumatic heart disease (RHD), moderate mitral regurgitation (MR), severe tricuspid regurgitation (TR), and pulmonary arterial hypertension (PAH)?

Perioperative Management for Mastectomy in RHD with Moderate MR, Severe TR, and PAH

This patient represents an extremely high-risk surgical candidate who should undergo mastectomy only at a specialized center with pulmonary hypertension expertise, cardiac anesthesiology, and intensive care capabilities, with mandatory multidisciplinary team planning and at least 24-48 hours of postoperative ICU monitoring. 1

Risk Stratification

This patient carries a perioperative cardiopulmonary complication rate of 38% and mortality risk of 7% based on the presence of PAH with severe TR 1. Key risk factors present include:

• Severe pulmonary hypertension (likely PA systolic pressure >50 mmHg given severe TR)
• Right ventricular dysfunction (implied by severe TR)
• Moderate mitral regurgitation requiring careful hemodynamic management
• Rheumatic heart disease with multivalvular involvement

The combination of severe TR with PAH creates particularly high risk for acute right heart failure and pulmonary hypertensive crisis perioperatively 2, 1.

Preoperative Optimization (Mandatory Before Elective Surgery)

Surgery should be delayed until complete optimization is achieved 1, 2:

Cardiac Assessment (within 3-6 months of surgery):

• Transthoracic echocardiography to quantify RV function, PA pressures, and valve severity
• Right heart catheterization to measure exact PA pressures and pulmonary vascular resistance
• Six-minute walk test and NT-proBNP for functional capacity assessment
• Evaluation by pulmonary hypertension specialist 3

Medical Optimization:

• Continue all PAH-specific therapy without interruption (phosphodiesterase-5 inhibitors, endothelin receptor antagonists, prostanoids) 1, 3
• Optimize volume status with diuretics to reduce RV preload while maintaining adequate cardiac output
• Achieve euvolemia - critical given the competing demands of MR (benefits from reduced afterload) and severe TR with PAH (requires careful preload management)

Multidisciplinary Planning Required:

Assemble team including cardiac anesthesiologist, cardiac surgeon (on standby), pulmonary hypertension specialist, and intensivist before surgery 2

Intraoperative Management

Anesthetic Approach:

Consider regional anesthesia with fascial plane blocks (pectoralis or serratus anterior blocks) to minimize general anesthesia requirements and maintain spontaneous ventilation 4. If general anesthesia required:

• Avoid rapid induction - use careful titration to prevent sudden drops in systemic vascular resistance
• Maintain spontaneous ventilation as long as possible before intubation
• Avoid positive pressure ventilation effects on RV afterload when possible

Hemodynamic Goals (Critical):

For the PAH/severe TR component:

• Maintain preload - avoid hypovolemia which precipitates RV failure
• Avoid increases in pulmonary vascular resistance - prevent hypoxia, hypercarbia, acidosis, hypothermia, pain
• Maintain systemic vascular resistance - use phenylephrine or norepinephrine for hypotension
• Maintain sinus rhythm - treat arrhythmias aggressively as RV is rate-dependent

For the moderate MR component:

• Avoid bradycardia - maintain heart rate 70-90 bpm to optimize forward flow
• Avoid excessive increases in afterload - balance with PAH management needs
• Maintain adequate preload without causing pulmonary edema

Monitoring (Mandatory):

• Arterial line for continuous blood pressure monitoring
• Central venous catheter for CVP monitoring and vasoactive drug administration
• Consider pulmonary artery catheter for continuous PA pressure and cardiac output monitoring 2, 5, 2
• Transesophageal echocardiography if available for real-time assessment of RV function and volume status 2

Pulmonary Vasodilator Strategy:

• Continue inhaled prostacyclins or convert to inhaled nitric oxide during general anesthesia 2
• Have intravenous pulmonary vasodilators immediately available (epoprostenol, milrinone)

Postoperative Management

Mandatory ICU admission for minimum 24-48 hours as cardiovascular complications often manifest 1-2 days post-procedure 2, 1, 2:

Monitoring:

• Continuous telemetry, arterial line, central venous pressure
• Serial echocardiography to assess RV function
• Strict fluid balance monitoring

Medical Management:

• Resume all PAH-specific medications immediately - do not withhold for NPO status; convert to IV/inhaled formulations if needed 1
• Optimize diuresis if signs of RV failure develop 1
• Initiate inotropic support with dobutamine if RV dysfunction progresses 1
• Aggressive pain control to prevent catecholamine surge and increased PVR 2

Watch for Complications:

• Acute RV failure (most common)
• Pulmonary hypertensive crisis
• Arrhythmias (particularly atrial fibrillation given rheumatic disease)
• Acute respiratory failure
• Prolonged intubation requirements

Critical Pitfalls to Avoid

1. Never proceed without PAH specialist evaluation and optimization - mortality risk is prohibitive otherwise 1, 3
2. Never withhold PAH medications perioperatively - even brief interruption can precipitate crisis 1
3. Never use neuraxial anesthesia alone - rapid sympathectomy and drop in SVR can be catastrophic in PAH 5
4. Never discharge before 24 hours - most complications occur in delayed fashion 2, 1, 2
5. Never allow hypoxia, hypercarbia, or acidosis - these dramatically increase PVR and precipitate RV failure 2

Risk-Benefit Discussion

For elective mastectomy, seriously consider delaying surgery unless it dramatically improves quality of life or is for cancer with metastatic potential 2, 6. The 7% mortality risk and 38% morbidity risk must be weighed against surgical benefits 1. If cancer-related and urgent/semi-urgent, proceed with above precautions at experienced center only 6.